Clinical trial · Interventional
Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury
Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury After Therapy With Docetaxel and Cisplatin for Nasopharyngeal Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The most common toxicity of TP (docetaxel and cisplatin) chemotherapy is chemotherapy-induced liver injury. However, patients don't always experience same chemotherapy-induced liver injury for the same drugs. Therefore, the investigators designed the present study to clarify risk factors associated with the development of severe hepatotoxicity after therapy with docetaxel and cisplatin for nasopharyngeal carcinoma (NPC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Injury, Drug-Induced | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| docetaxel and cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Study Population
- description
- Patients with advanced nasopharyngeal carcinoma scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy
- interventionNames
- Drug: docetaxel and cisplatin
Primary outcomes (4)
- measure
- Relationship of white blood cell level and chemotherapy-induced liver injury
- timeFrame
- 3 weeks
- description
- White blood cell level (cells/L) and liver function (such as ALT, AST, ALP, and bilirubin levels) will be tested before (1-3 days) and after (21 ± 3 days) first cycle of chemotherapy, and the relationship of white cell level fluctuation and liver injury will be investigated.
- measure
- Relationship of albumin level and chemotherapy-induced liver injury
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced nasopharyngeal carcinoma. * Patients scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy. * Normal liver function biomarkers including ALT,AST,ALP,TBIL before recruitment. * Minimum age of 18 years. * Life expectancy at least 3 months. Exclusion Criteria: * Patients previously received chemotherapy * Patients who have liver metastases. * Patients who take other drugs that may affect liver function
References
Publications (0)
Data not yet available